Children’s Mercy announced on Apr. 17 that it has signed an exclusive licensing agreement with Vima Therapeutics to bring a new treatment for movement disorders, including dystonia and Parkinson’s disease, closer to market.
The agreement involves VIM0423, an oral therapy developed by researchers at Children’s Mercy. The hospital said the U.S. Food and Drug Administration has granted the treatment Fast Track designation to move forward into clinical trials.
Steven Leeder, chief scientific officer for Children’s Mercy Research Institute, said in a release: “This agreement accelerates innovation from the lab to the bedside, turning discovery into care. It’s more than a licensing deal; it’s a testament to what’s possible when innovation and compassion come together.”
The licensing deal is intended to help advance research efforts into practical treatments that could benefit both children and adults living with movement disorders such as dystonia or Parkinson’s disease.
No further details about trial timelines or next steps were provided in the announcement.
